The emerging roles of γδ T cells in cancer immunotherapy
S Mensurado, R Blanco-Domínguez… - Nature Reviews Clinical …, 2023 - nature.com
Current cancer immunotherapies are primarily predicated on αβ T cells, with a stringent
dependence on MHC-mediated presentation of tumour-enriched peptides or unique …
dependence on MHC-mediated presentation of tumour-enriched peptides or unique …
Innate and adaptive immune cells in the tumor microenvironment
Most tumor cells express antigens that can mediate recognition by host CD8+ T cells.
Cancers that are detected clinically must have evaded antitumor immune responses to grow …
Cancers that are detected clinically must have evaded antitumor immune responses to grow …
Gamma delta T-cell based cancer immunotherapy: past-present-future
J Saura-Esteller, M De Jong, LA King… - Frontiers in …, 2022 - frontiersin.org
γδ T-cells directly recognize and kill transformed cells independently of HLA-antigen
presentation, which makes them a highly promising effector cell compartment for cancer …
presentation, which makes them a highly promising effector cell compartment for cancer …
γδ T cells: origin and fate, subsets, diseases and immunotherapy
Y Hu, Q Hu, Y Li, L Lu, Z **ang, Z Yin… - … and Targeted Therapy, 2023 - nature.com
The intricacy of diseases, shaped by intrinsic processes like immune system exhaustion and
hyperactivation, highlights the potential of immune renormalization as a promising strategy …
hyperactivation, highlights the potential of immune renormalization as a promising strategy …
Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies
Clinical responses to checkpoint inhibitors used for cancer immunotherapy seemingly
require the presence of αβT cells that recognize tumour neoantigens, and are therefore …
require the presence of αβT cells that recognize tumour neoantigens, and are therefore …
Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer
Abstract Vγ9Vδ2 T cells are promising candidates for cellular tumor immunotherapy. Due to
their HLA-independent mode of action, allogeneic Vγ9Vδ2 T cells can be considered for …
their HLA-independent mode of action, allogeneic Vγ9Vδ2 T cells can be considered for …
Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma
Immunotherapy is now the standard of care for advanced hepatocellular carcinoma (HCC),
yet many patients fail to respond. A major unmet goal is the boosting of T-cells with both …
yet many patients fail to respond. A major unmet goal is the boosting of T-cells with both …
Unconventional T cell targets for cancer immunotherapy
Most studies on the immunotherapeutic potential of T cells have focused on CD8 and CD4 T
cells that recognize peptide antigens (Ag) presented by polymorphic major histocompatibility …
cells that recognize peptide antigens (Ag) presented by polymorphic major histocompatibility …
Gamma-delta (γδ) T cells: friend or foe in cancer development?
Y Zhao, C Niu, J Cui - Journal of translational medicine, 2018 - Springer
Background γδ T cells are a distinct subgroup of T cells containing T cell receptors (TCRs) γ
and TCR δ chains with diverse structural and functional heterogeneity. As a bridge between …
and TCR δ chains with diverse structural and functional heterogeneity. As a bridge between …
Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell–mediated antitumor immune response
A De Gassart, KS Le, P Brune, S Agaugué… - Science Translational …, 2021 - science.org
Gamma delta T (γδ T) cells are among the most potent cytotoxic lymphocytes. Activating anti–
butyrophilin 3A (BTN3A) antibodies prime diverse tumor cell types to be killed by Vγ9Vδ2 T …
butyrophilin 3A (BTN3A) antibodies prime diverse tumor cell types to be killed by Vγ9Vδ2 T …